Access and barriers to genomic classifiers for breast cancer and prostate cancer in India

Author:

Ranganathan Sruthi1ORCID,Dee Edward Christopher2,Debnath Neha3,Patel Tej A.4,Jain Bhav5,Murthy Vedang6

Affiliation:

1. Department of Medicine Cambridge University Cambridge UK

2. Department of Radiation Oncology Memorial Sloan Kettering Cancer Center New York New York USA

3. Department of Medicine Icahn School of Medicine at Mount Sinai (Morningside/West) New York New York USA

4. Department of Healthcare Management & Policy University of Pennsylvania Philadelphia Pennsylvania USA

5. Department of Health Policy Stanford University School of Medicine Stanford California USA

6. Department of Radiation Oncology, ACTREC, Tata Memorial Centre Homi Bhabha National Institute Mumbai India

Abstract

AbstractThe incidence of cancer in general, including breast and prostate cancer specifically, is increasing in India. Breast and prostate cancers have genomic classifiers developed to guide therapy decisions. However, these genomic classifiers are often inaccessible in India due to high cost. These classifiers may also be less suitable to the Indian population, as data primarily from patients in wealthy Western countries were used in developing these genomic classifiers. In addition to the limitations in using these existing genomic classifiers, developing and validating new genomic classifiers for breast and prostate cancer in India is challenging due to the heterogeneity in the Indian population. However, there are steps that can be taken to address the various barriers that currently exist for accurate, accessible genomic classifiers for cancer in India.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference58 articles.

1. Epidemiology of breast cancer in Indian women

2. Demography and disease characteristics of prostate cancer in India;Hariharan K;Indian J Urol,2016

3. Genomic sequencing in clinical practice: applications, challenges, and opportunities

4. A 22 gene‐expression assay, decipher® (GenomeDx biosciences) to predict five‐year risk of metastatic prostate cancer in men treated with radical prostatectomy;Marrone M;PLoS Curr,2015

5. Prolaris test for prostate cancer risk assessment;Ebell MH;Am Fam Physician,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3